Date: 0000-00-00
Type of information: Nomination
Compound:
Company: Ascendis Pharma (Denmark)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 25, 2016, Ascendis Pharma announced that it has appointed Jonathan A. Leff, M.D. as Chief Medical Officer. Dr. Leff most recently served as InterMune's Executive Vice President, Research and Development from February 2012 to March 2015, where he led the development of Esbriet® for the treatment of idiopathic pulmonary fibrosis through a successful Phase 3 trial, resubmission of a New Drug Application and eventual approval from the FDA. Prior to his role at InterMune, he served as Chief Medical Officer of KaloBios Pharmaceuticals and Halozyme Therapeutics. Dr. Leff began his industry career working in various clinical development and medical affairs roles of increasing responsibility at Merck&Co., Amgen, and Roche. Dr. Leff earned a B.A. in Chemistry from the University of Pennsylvania, and received his M.D. from the University of Pennsylvania School of Medicine. He completed his medical training in Internal Medicine and Pulmonary and Critical Care Medicine at the University of Colorado, Denver. Additionally, Ascendis announced that Dr. Michael Beckert, Ascendis Pharma's former acting Chief Medical Officer, will continue his consulting role with the company with a focus on leading the company's European clinical operations.
Financial terms:
Latest news:
